Managers / Q1 2022 · view latest →
Gates Foundation
CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100
Summary
Gates Foundation reported $186M in U.S.-listed holdings across 11 positions for Q1 2022.
The portfolio is heavily concentrated: VIR alone accounts for 21.6% of reported value.
The book was largely unchanged from Q4 2021.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 36.0% · $67M
- ADR · 35.2% · $66M
- Common Stock · 28.8% · $54M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VIRVIR BIOTECHNOLOGY INC | ADDED | +881.4K | 1.56M | +$12M | $40M |
| CUREVAC N V | TRIMMED | −1.42M | 1.71M | −$74M | $34M |
| ATRECA INC | HELD | −65.3K | 1.33M | +$0 | $4M |
| SERASERA PROGNOSTICS INC | HELD | +20.0K | 799.8K | −$2M | $3M |
| IMCRIMMUNCORE HLDGS PLC | HELD | +0 | 576.9K | −$39M | $17M |
| LUMIRADX LIMITED | HELD | +0 | 5.57M | −$16M | $33M |
| BNTXBIONTECH SE | HELD | +0 | 148.7K | −$13M | $25M |
| EXSCIENTIA | HELD | +0 | 1.59M | −$9M | $23M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | VIRVIR BIOTECHNOLOGY INChistory → | COM | 21.56% | $40M | 1.56M |
| 2 | CUREVAC N V | COM | 18.01% | $34M | 1.71M |
| 3 | LUMIRADX LIMITED | SHS | 17.96% | $33M | 5.57M |
| 4 | BNTXBIONTECH SEhistory → | SPONSORED ADS | 13.66% | $25M | 148.7K |
| 5 | EXSCIENTIA | ADS | 12.31% | $23M | 1.59M |
| 6 | IMCRIMMUNCORE HLDGS PLChistory → | ADS | 9.25% | $17M | 576.9K |
| 7 | BFLYBUTTERFLY NETWORK INChistory → | CL A COM | 2.58% | $5M | 1.01M |
| 8 | ATRECA INC | CL A COM | 2.26% | $4M | 1.33M |
| 9 | SERASERA PROGNOSTICS INChistory → | CL A COM | 1.61% | $3M | 799.8K |
| 10 | AMYRIS INC | COM NEW | 0.70% | $1M | 292.4K |
| 11 | ZYUSDZYMERGEN INC | COM | 0.11% | $200,000 | 60.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $60M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $84M | 8 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $90M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $84M | 9 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $126M | 9 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $113M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $130M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 10 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $130M | 9 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 11 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $330M | 11 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $342M | 10 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $692M | 8 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $656M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $438M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.